Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Lung Neoplasms 83Lymphoma 76Head and Neck Neoplasms 76Glioblastoma 75Squamous Cell Carcinoma of Head and Neck 71Breast Neoplasms 71Rectal Neoplasms 67Esophageal Neoplasms 63Prostatic Neoplasms 59Leukemia 57Central Nervous System Neoplasms 54Pancreatic Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 43Lymphoma, Large B-Cell, Diffuse 43Hodgkin Disease 42Lymphoma, Follicular 41Brain Neoplasms 40Leukemia, Lymphocytic, Chronic, B-Cell 39Esophageal Squamous Cell Carcinoma 39Colorectal Neoplasms 38Burkitt Lymphoma 37Gliosarcoma 36Lymphoma, Large-Cell, Immunoblastic 33Uterine Cervical Neoplasms 31Neoplasms 31Adenocarcinoma Of Esophagus 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 29

Interventions

pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Gemcitabine 1Cystectomy 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Infiltrating Bladder Urothelial Carcinoma × Radiotherapy × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡